LLMS Central - The Robots.txt for AI

protagonist-inc.com

Last updated: 11/16/2026valid

Independent Directory - Important Information

This llms.txt file was publicly accessible and retrieved from protagonist-inc.com. LLMS Central does not claim ownership of this content and hosts it for informational purposes only to help AI systems discover and respect website policies.

This listing is not an endorsement by protagonist-inc.com and they have not sponsored this page. We are an independent directory service with no affiliation to the listed domain.

Copyright & Terms: Users should respect the original terms of service of protagonist-inc.com. If you believe there is a copyright or terms of service violation, please contact us at support@llmscentral.com for prompt removal. Domain owners can also claim their listing.

Current llms.txt Content

# www.protagonist-inc.com

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.

## Pages


- [Product Pipeline](http://www.protagonist-inc.com/product-pipeline): Product Pipeline - Protagonist Therapeutics Inc.

- [News](http://www.protagonist-inc.com/news): News - Protagonist Therapeutics Inc.

- [Stock Info](http://www.protagonist-inc.com/stock-info): Stock Info - Protagonist Therapeutics Inc.

- [Press Releases](http://www.protagonist-inc.com/press-releases): Press Releases - Protagonist Therapeutics Inc.

- [Publications](http://www.protagonist-inc.com/publications): Publications - Protagonist Therapeutics Inc.

- [Executive Team](http://www.protagonist-inc.com/executive-team): Executive Team - Protagonist Therapeutics Inc.

- [Careers](http://www.protagonist-inc.com/careers): Careers - Protagonist Therapeutics Inc.

- [Terms of Use](http://www.protagonist-inc.com/terms-of-use): Terms of Use - Protagonist Therapeutics Inc.

- [Technology](http://www.protagonist-inc.com/technology): Technology - Protagonist Therapeutics Inc.

- [Areas of Focus](http://www.protagonist-inc.com/areas-of-focus): Areas of Focus - Protagonist Therapeutics Inc.

- [ESG](http://www.protagonist-inc.com/esg): ESG - Protagonist Therapeutics Inc.

- [Innovation](http://www.protagonist-inc.com/innovation): Innovation - Protagonist Therapeutics Inc.

- [Governance](http://www.protagonist-inc.com/governance): Governance - Protagonist Therapeutics Inc.

- [Community](http://www.protagonist-inc.com/community): Community - Protagonist Therapeutics Inc.

- [Leadership](http://www.protagonist-inc.com/leadership): Leadership - Protagonist Therapeutics Inc.

- [Investor Contacts](http://www.protagonist-inc.com/investor-contacts): Investor Contacts - Protagonist Therapeutics Inc.

- [Financials](http://www.protagonist-inc.com/financials): Financials - Protagonist Therapeutics Inc.

- [Blood Cancer Awareness - What You Need to Know Now](http://www.protagonist-inc.com/blood-cancer-awareness-what-you-need-to-know-now): Blood Cancer Awareness - Protagonist Therapeutics Inc.

- [Join Our Team](http://www.protagonist-inc.com/join-our-team): Join Our Team - Protagonist Therapeutics Inc.

- [Privacy Policy](http://www.protagonist-inc.com/privacy-policy): Privacy Policy - Protagonist Therapeutics Inc.

- [Expanded Access Policy](http://www.protagonist-inc.com/expanded-access-policy): Privacy Policy - Protagonist Therapeutics Inc.

- [Culture & Values](http://www.protagonist-inc.com/culture-values): Culture & Values - Protagonist Therapeutics Inc.

- [Clinical Trials](http://www.protagonist-inc.com/clinical-trials): Clinical Trials - Protagonist Therapeutics Inc.

- [Locations](http://www.protagonist-inc.com/locations): Locations - Protagonist Therapeutics Inc.

- [Contact](http://www.protagonist-inc.com/contact): Contact - Protagonist Therapeutics Inc.

- [Board of Directors](http://www.protagonist-inc.com/board-of-directors): Board of  Directors - Protagonist Therapeutics Inc.

- [Metabolism Scientific Advisory Board](http://www.protagonist-inc.com/metabolism-scientific-advisory-board): Board of  Directors - Protagonist Therapeutics Inc.

- [Home](http://www.protagonist-inc.com/)

- [Analyst Coverage](http://www.protagonist-inc.com/analyst-coverage): Analyst Coverage - Protagonist Therapeutics Inc.

- [Scientific Posters and Presentations](http://www.protagonist-inc.com/scientific-posters-and-presentations): Scientific Posters & Presentations - Protagonist Therapeutics Inc.

- [Corporate Events & Presentations](http://www.protagonist-inc.com/events-presentations): Events & Presentations - Protagonist Therapeutics Inc.

- [Investor Email Alerts](http://www.protagonist-inc.com/investor-email-alerts): Investor Email Alerts - Protagonist Therapeutics Inc.


## Blog Posts


- [ICOTYDE® named one of TIME Magazine's Best Inventions of 2026](http://www.protagonist-inc.com/icotyde-named-one-of-time-magazine-s-best-inventions-of-2026): ICOTYDE® named one of TIME Magazine's Best Inventions of 2026

- [VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy](http://www.protagonist-inc.com/verify-a-phase-iii-trial-of-rusfertide-versus-placebo-in-phlebotomy-dependent-patients-with-polycythemia-vera-receiving-standard-of-care-therapy)

- [Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/improvements-in-clinical-and-patient-reported-outcomes-and-durability-of-response-with-the-targeted-oral-peptide-icotrokinra-in-adolescents-with-moderate-to-severe-plaque-psoriasis)

- [Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings](http://www.protagonist-inc.com/durability-of-response-to-icotrokinra-for-high-impact-site-psoriasis-1-year-iconic-total-findings)

- [Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderate-to-severe-plaque-psoriasis)

- [Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/durability-of-response-to-icotrokinra-in-adults-with-moderate-to-severe-plaque-psoriasis)

- [Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites](http://www.protagonist-inc.com/safety-of-icotrokinra-through-1-year-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-and-psoriasis-affecting-high-impact-sites-pooled-results-across-the-iconic-lead-iconic-total-and-iconic)

- [Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis](http://www.protagonist-inc.com/phase-2-trial-of-icotrokinra-for-patients-with-ulcerative-colitis)

- [WSJ: The Peptide Boom That Isn’t About Your Muscles](http://www.protagonist-inc.com/wsj-the-peptide-boom-that-isnt-about-your-muscles)

- [Protagonist at the Cantor Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-cantor-global-healthcare-conference)

- [Protagonist at the Citi Biopharma Back to School Summit](http://www.protagonist-inc.com/protagonist-at-the-citi-biopharma-back-to-school-summit)

- [U.S. FDA Approves MIMRYLO™ (rusfertide)](http://www.protagonist-inc.com/events-presentations/u-s-fda-approves-mimrylotm-rusfertide)

- [US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)](http://www.protagonist-inc.com/events-presentations/us-fda-approval-of-mimrylotm-rusfertide-for-treatment-of-erythrocytosis-in-adults-with-polycythemia-vera-pv): US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)

- [2026 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2026-european-hematology-association-eha-meeting)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/jefferies-global-healthcare-conference)

- [CEO Dinesh Patel Joins CNBC’s Fast Money](http://www.protagonist-inc.com/ceo-dinesh-patel-joins-cnbcs-fast-money)

- [BioSpace covers ICOTYDE™ FDA Approval](http://www.protagonist-inc.com/news/biospace-covers-icotydetm-fda-approval)

- [U.S. FDA Approves ICOTYDE™ (icotrokinra)](http://www.protagonist-inc.com/news/us-fda-approves-icotydetm-icotrokinra)

- [Barclays Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/barclays-global-healthcare-conference)

- [Barclays 28th Annual Global Healthcare Conference](http://www.protagonist-inc.com/barclays-28th-annual-global-healthcare-conference)

- [Citizens Life Sciences Conference](http://www.protagonist-inc.com/citizens-life-sciences-conference)

- [Jefferies Biotech on the Beach Summit](http://www.protagonist-inc.com/jefferies-biotech-on-the-beach-summit)

- [Leerink Global Healthcare Conference](http://www.protagonist-inc.com/leerink-global-healthcare-conference-miami-fl)

- [TD Cowen 46th Annual Health Care Conference; Boston, MA](http://www.protagonist-inc.com/td-cowen-46th-annual-health-care-conference-boston-ma-march-2-4-2026)

- [Protagonist CEO Dinesh V. Patel and Chief Discovery Officer Ashok Bhandari Speak with BiotechTV](http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-and-chief-discovery-officer-ashok-bhandari-speak-with-biotechtv)

- [Protagonist Speaks to BioSpace at #JPM26](http://www.protagonist-inc.com/jpm26-protagonist-has-a-400m-decision-to-make-its-a-no-brainer)

- [Protagonist at the J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-j-p-morgan-healthcare-conference)

- [Protagonist at the Evercore Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-evercore-healthcare-conference)

- [Protagonist at the Citi Global Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-citi-global-healthcare-conference)

- [TD Cowen Advancements in Obesity Summit](http://www.protagonist-inc.com/events-presentatuions/td-cowen-advancements-in-obesity-summit)

- [Protagonist CEO Dinesh V. Patel on our programs and culture of partnering at #Jefferies25](http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-on-our-programs-and-culture-of-partnering-at-jefferies25)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/protagonist-at-the-jefferies-global-healthcare-conference)

- [Protagonist at the TD Cowen Immunology & Inflammation Summit](http://www.protagonist-inc.com/events-presentations/td-cowen-immunology-inflammation-summit): Protagonist at TD Cowen Immunology & Inflammation Summit

- [PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis](http://www.protagonist-inc.com/ptg-100-an-oral-a4b7-antagonist-peptide-preclinical-development-and-phase-1-and-2a-studies-in-ulcerative-colitis): PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis

- [Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers](http://www.protagonist-inc.com/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers)

- [Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial](http://www.protagonist-inc.com/rusfertide-for-the-treatment-of-iron-overload-in-hfe-related-haemochromatosis-an-open-label-multicentre-proof-of-concept-phase-2-trial)

- [Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera](http://www.protagonist-inc.com/rusfertide-a-hepcidin-mimetic-for-control-of-erythrocytosis-in-polycythemia-vera)

- [Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians](http://www.protagonist-inc.com/contemporary-challenges-in-polycythemia-vera-management-from-the-perspective-of-patients-and-physicians)

- [Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study](http://www.protagonist-inc.com/pharmacokinetics-pharmacodynamics-and-tolerability-of-an-aqueous-formulation-of-rusfertide-ptg-300-a-hepcidin-mimetic-in-healthy-volunteers-a-double-blind-first-in-human-study)

- [Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers](http://www.protagonist-inc.com/pharmacokinetics-and-pharmacodynamics-of-rusfertide-a-hepcidin-mimetic-following-subcutaneous-administration-of-a-lyophilized-powder-formulation-in-healthy-volunteers)

- [Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.](http://www.protagonist-inc.com/multiple-dose-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-subcutaneous-rusfertide-a-hepcidin-mimetic-in-healthy-subjects)

- [An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis](http://www.protagonist-inc.com/an-oral-interleukin-23-receptor-antagonist-peptide-for-plaque-psoriasis)

- [JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans](http://www.protagonist-inc.com/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans)

- [FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis](http://www.protagonist-inc.com/frontier-2-a-phase-2b-long-term-extension-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis)

- [Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.](http://www.protagonist-inc.com/oral-peptide-therapeutics-as-an-emerging-treatment-modality-in-immune-mediated-inflammatory-diseases-a-narrative-review)

- [Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively  Blocks Interleukin-23 Receptor and Inhibits Signaling.](http://www.protagonist-inc.com/translational-pharmacokinetics-of-icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-interleukin-23-receptor-and-inhibits-signaling)

- [2025 Society For Investigative Dermatology](http://www.protagonist-inc.com/2025-society-for-investigative-dermatology)

- [2025 European Academy of Dermatology and Venerology Congress](http://www.protagonist-inc.com/2025-european-academy-of-dermatology-and-venerology-congress)

- [63rd American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/63rd-american-society-of-hematology-annual-meeting-and-exposition)

- [64th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/64th-american-society-of-hematology-annual-meeting-and-exposition)

- [65th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/65th-american-society-of-hematology-annual-meeting-and-exposition)

- [63rd American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/63rd-american-society-of-hematology-ash-annual-meeting-and-exposition)

- [American Society of Clinical Oncology 2022 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2022-annual-meeting)

- [2022 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2022-european-hematology-association-eha-meeting)

- [Society of Hematologic Oncology (SOHO) 2022 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2022-annual-meeting)

- [64th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/64th-american-society-of-hematology-ash-annual-meeting-and-exposition)

- [2023 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2023-european-hematology-association-eha-meeting)

- [Society of Hematologic Oncology (SOHO) 2023 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2023-annual-meeting)

- [15th International Congress on Myeloproliferative Neoplasms (MPN Congress)](http://www.protagonist-inc.com/15th-international-congress-on-myeloproliferative-neoplasms-mpn-congress)

- [65th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/65th-american-society-of-hematology-ash-annual-meeting-and-exposition)

- [10th Translational Research Conference: Myeloproliferative Neoplasms](http://www.protagonist-inc.com/10th-translational-research-conference-myeloproliferative-neoplasms)

- [American Society of Clinical Oncology 2024 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2024-annual-meeting)

- [2024 European Hematology Association (EHA) Meeting](http://www.protagonist-inc.com/2024-european-hematology-association-eha-meeting)

- [2024 American College of Clinical Pharmacology (ACCP) Annual Meeting](http://www.protagonist-inc.com/2024-american-college-of-clinical-pharmacology-accp-annual-meeting)

- [16th International Congress on Myeloproliferative Neoplasms (MPN Congress)](http://www.protagonist-inc.com/16th-international-congress-on-myeloproliferative-neoplasms-mpn-congress)

- [66th American Society of Hematology (ASH) Annual Meeting and Exposition](http://www.protagonist-inc.com/66th-american-society-of-hematology-ash-annual-meeting-and-exposition)

- [American Society of Clinical Oncology 2025 Annual Meeting](http://www.protagonist-inc.com/american-society-of-clinical-oncology-2025-annual-meeting)

- [MPN Workshop of the Carolinas 2025](http://www.protagonist-inc.com/mpn-workshop-of-the-carolinas-2025)

- [Society of Hematologic Oncology (SOHO) 2025 Annual Meeting](http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2025-annual-meeting)

- [Protagonist at the H.C. Wainwright Global Investment Conference](http://www.protagonist-inc.com/h-c-wainwright-global-investment-conference)

- [Protagonist at the Citigroup 2025 Biopharma Conference](http://www.protagonist-inc.com/protagonist-at-the-citigroup-2025-biopharma-conference)

- [Protagonist Announces Nomination of PN-477, an Oral and Injectable Peptide Development Candidate for Obesity](http://www.protagonist-inc.com/protagonist-announces-nomination-of-pn-477-an-oral-and-injectable-peptide-development-candidate-for-obesity)

- [Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate](http://www.protagonist-inc.com/events/protagonist-therapeutics-to-host-conference-call-to-announce-an-oral-obesity-development-candidate)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-at-the-jefferies-global-healthcare-conference)

- [CEO Dinesh V. Patel Speaks With BiotechTV at #ASCO25](http://www.protagonist-inc.com/news/ceo-dinesh-v-patel-speaks-with-biotechtv-at-asco25)

- [Post-ASCO Update: Phase 3 VERIFY Study Results](http://www.protagonist-inc.com/events-presentations/post-asco-update-phase-3-verify-study-results)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-2025)

- [Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025](http://www.protagonist-inc.com/events-presentations/plenary-presentation-on-verify-phase-3-study-with-rusfertide-at-asco-2025)

- [Protagonist Therapeutics Is One of Fast Company’s Most Innovative Companies of 2025](http://www.protagonist-inc.com/news/protagonist-therapeutics-is-one-of-fast-companys-most-innovative-companies-of-2025)

- [Protagonist Investor Conference Call and Webcast](http://www.protagonist-inc.com/events-presentations/protagonist-investor-conference-call-and-webcast)

- [Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide](http://www.protagonist-inc.com/events-presentations/investor-event-with-kol-insights-on-polycythemia-vera-pv-and-the-hepcidin-mimetic-rusfertide)

- [Protagonist at the J.P. Morgan 43rd Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jpm-43rd-annual-healthcare-conference): Protagonist at J.P. Morgan 43rd Annual Healthcare Conference

- [ASH REVIVE Final Analysis Poster](http://www.protagonist-inc.com/publications/ash-revive-final-analysis-poster)

- [Endpoints News: J&J and Protagonist Announce Phase 3 Trial Results for icotrokinra (JNJ-2113, formerly PN-235)](http://www.protagonist-inc.com/news/jj-and-protagonist-announce-phase-3-rial-results-for-icotrokinra)

- [Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate](http://www.protagonist-inc.com/events-presenations/protagonist-announces-nomination-of-pn-881-a-potential-best-in-class-oral-peptide-il-17-antagonist-development-candidate)

- [Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor](http://www.protagonist-inc.com/news/protagonist-announces-positive-topline-results-from-phase-3-iconic-studies-of-icotrokinra-jnj-2113-a-first-in-class-investigational-targeted-oral-peptide-that-selectively-blocks-the-il-23-receptor)

- [Protagonist at the The 66th Annual American Society of Hematology (ASH) Annual Meeting](http://www.protagonist-inc.com/events-presentations/the-66th-annual-american-society-of-hematology-ash-annual-meeting)

- [Protagonist at the H.C. Wainwright 26th Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-26th-annual-global-investment-conference)

- [Nature: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans](http://www.protagonist-inc.com/news/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans)

- [EHA 2024 Oral Presentation: Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients](http://www.protagonist-inc.com/events-presentations/eha-2024-oral-presentation-updated-long-term-results-from-the-phase-2-revive-study-investigating-the-hepcidin-mimetic-rusfertide-in-polycythemia-vera-patients): EHA 2024 Oral Presentation: Updated Long-Term Results from the Phase 2 REVIVE Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients

- [Protagonist at the The Citizens JMP Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference-may-13-2024)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-june-6-2024)

- [Protagonist at the Jefferies Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference)

- [Corporate Presentation](http://www.protagonist-inc.com/corporate-presentation)

- [Protagonist at the The Citizens JMP Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference)

- [Protagonist at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-2nd-annual-autoimmune-inflammatory-disease-virtual-conference)

- [6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference](http://www.protagonist-inc.com/events-presentations/6th-annual-guggenheim-healthcare-talks-annual-biotechnology-conference)

- [Protagonist at the 42nd Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/42nd-annual-j-p-morgan-healthcare-conference-jan-8-2023)

- [ASH 2023 Oral Presentation: Durability of Hematocrit Control in Polycythemia Vera With the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results From the REVIVE Study](http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-durability-of-hematocrit-control-in-polycythemia-vera-with-the-first-in-class-hepcidin-mimetic-rusfertide-two-year-follow-up-results-from-the-revive-study)

- [ASH 2023 Oral Presentation: Real-World Analysis of Thromboembolic Event Rates in Patients in the United States with Polycythemia Vera](http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-real-world-analysis-of-thromboembolic-event-rates-in-patients-in-the-united-states-with-polycythemia-vera)

- [ASH 2023 Poster Presentation: Rusfertide Improves Markers Of Iron Deficiency In Patients With Polycythemia Vera](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-rusfertide-improves-markers-of-iron-deficiency-in-patients-with-polycythemia-vera)

- [ASH 2023 Poster Presentation: Prevalence Of Second Cancers In Patients With Polycythemia Vera (PV): A Retrospective Analysis Of Us Real-World Claims Data](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-prevalence-of-second-cancers-in-patients-with-polycythemia-vera-pv-a-retrospective-analysis-of-us-real-world-claims-data)

- [ASH 2023 Poster Presentation: Iron Restricted Erythropoiesis Under Hepcidin Mimetic Treatment (PN23114) Improves Disease Parameters In A Mouse Model For Sickle Cell Disease](http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-iron-restricted-erythropoiesis-under-hepcidin-mimetic-treatment-pn23114-improves-disease-parameters-in-a-mouse-model-for-sickle-cell-disease)

- [Protagonist Therapeutics CEO Dinesh V. Patel on our hepcidin memetic and oral IL-23 program at #ASH23](http://www.protagonist-inc.com/news/protagonist-therapeutics-ceo-on-its-hepcidin-memetic-at-ash23-and-oral-il23-program-in-i-i)

- [J&J notebook: Highlights from a day of pipeline and strategy discussion](http://www.protagonist-inc.com/news/j-j-notebook-highlights-from-a-day-of-pipeline-and-strategy-discussion)

- [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference082b4611)

- [Summary of Malignancies Observed Across 5 Phase 2 Open Label Clinical Trials of the Hepcidin Mimetic Rusfertide](http://www.protagonist-inc.com/publications/summary-of-malignancies-observed-across-5-phase-2-open-label-clinical-trials-of-the-hepcidin-mimetic-rusfertide)

- [Oral IL 23 Receptor Peptide Antagonist JNJ 2113: The Journey from De Novo Discovery to Phase 3 Clinical Development Program](http://www.protagonist-inc.com/publications/oral-il-23-receptor-peptide-antagonist-jnj-2113-the-journey-from-de-novo-discovery-to-phase-3-clinical-development-program)

- [JNJ 77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients With Plaque Psoriasis](http://www.protagonist-inc.com/publications/jnj-77242113-treatment-induces-a-strong-systemic-pharmacodynamic-response-versus-placebo-in-serum-samples-of-patients-with-plaque-psoriasis)

- [A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study of Oral JNJ 77242113 for the Treatment of Moderate to Severe Plaque Psoriasis](http://www.protagonist-inc.com/publications/a-phase-2-randomized-placebo-controlled-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis)

- [Improving Access to Medicines, Ensuring Diverse Representation](http://www.protagonist-inc.com/news/improving-access-to-medicines-ensuring-diverse-representation)

- [Protagonist: Inclusion by the Numbers](http://www.protagonist-inc.com/news/protagonist-inclusion-by-the-numbers)

- [Blood Cancer Awareness - What You Need to Know Now](http://www.protagonist-inc.com/news/blood-cancer-awareness-what-you-need-to-know-now)

- [Join Our Polycythemia Vera VERIFY Clinical Study](http://www.protagonist-inc.com/news/join-our-polycythemia-vera-verify-clinical-study)

- [Cancer Moonshot: How We’re Helping Patients](http://www.protagonist-inc.com/news/cancer-moonshot-how-were-helping-patients)

- [Polycythemia Vera: Mechanism of Disease](http://www.protagonist-inc.com/news/polycythemia-vera-mechanism-of-disease)

- [CEO Dinesh Patel Talks Culture, Collaboration and Courage](http://www.protagonist-inc.com/news/ceo-dinesh-patel-talks-culture-collaboration-and-courage)

- [Formulas for Success from Biotechs that Leaped in Value Despite the Downturn](http://www.protagonist-inc.com/news/formulas-for-success-from-biotechs-that-leaped-in-value-despite-the-downturn)

- [Amgen tipped to keep Otezla market share in fight with BMS' Sotyktu, leaving opportunity for J&J](http://www.protagonist-inc.com/news/amgen-tipped-to-keep-otezla-market-share-in-fight-with-bms-sotyktu-leaving-opportunity-for-j-j)

- [Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide: Blinded Randomizated Withdrawal Results of the Phase 2 Revive Study](http://www.protagonist-inc.com/publications/targeted-therapy-of-uncontrolled-erythrocytosis-in-polycythemia-vera-with-the-hepcidin-mimetic-rusfertide-blinded-randomizated-withdrawal-results-of-the-phase-2-revive-study)

- [Protagonist at the H.C. Wainwright 25th Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-25th-annual-global-investment-conference)

- [Wells Fargo 2023 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/wells-fargo-2023-healthcare-conference)

- [Rusfertide in PV (REVIVE) - Late Breaking Oral Presentation June 11, 2023](http://www.protagonist-inc.com/publications/rusfertide-in-pv-revive-late-breaking-oral-presentation-june-11-2023)

- [Pharmacokinetic and Pharmacodynamic Effects of Rusfertide In Polycythemia Vera: Results from an Ongoing Phase 2 Study in Patients with Elevated Hematocrit Values](http://www.protagonist-inc.com/publications/pharmacokinetic-and-pharmacodynamic-effects-of-rusfertide-in-polycythemia-vera-results-from-an-ongoing-phase-2-study-in-patients-with-elevated-hematocrit-values)

- [Rusfertide (PTG-300) Improves Polycythemia Vera (PV) Related Symptoms in PV Patients](http://www.protagonist-inc.com/publications/rusfertide-ptg-300-improves-polycythemia-vera-pv-related-symptoms-in-pv-patients)

- [Protagonist at the Jefferies Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference-2023)

- [2023 World Congress of Dermatology](http://www.protagonist-inc.com/events-presentations/2023-world-congress-of-dermatology)

- [First-In-Class Oral Peptide Systemically Targeting The IL-23 Pathway](http://www.protagonist-inc.com/publications/first-in-class-oral-peptide-systemically-targeting-the-il-23-pathway)

- [2023 Annual Congress of the European Hematology Association](http://www.protagonist-inc.com/events-presentations/2023-annual-congress-of-the-european-hematology-association)

- [Real‑World Treatments and Thrombotic Events in Polycythemia Vera Patients in the USA](http://www.protagonist-inc.com/publications/realworld-treatments-and-thrombotic-events-in-polycythemia-vera-patients-in-the-usa)

- [J.P. Morgan 2023 Healthcare Conference Company Presentation](http://www.protagonist-inc.com/events-presentations/j-p-morgan-2023-healthcare-conference-company-presentation)

- [ASH 2022 Poster Presentation: Rusfertide analog-PN23114 as a hepcidin mimetic provides efficacy benefits in conjunction with phlebotomy in mouse model for hereditary hemochromatosis](http://www.protagonist-inc.com/ash-2022-poster-presentation-rusfertide-analog-pn23114-as-a-hepcidin-mimetic-provides-efficacy-benefits-in-conjunction-with-phlebotomy-in-mouse-model-for-hereditary-hemochromatosis)

- [32nd Annual Piper Sandler Healthcare Conference](http://www.protagonist-inc.com/events-presentations/32nd-annual-piper-sandler-healthcare-conference)

- [Raymond James Human Health Innovations Conference](http://www.protagonist-inc.com/events-presentations/raymond-james-human-health-innovations-conference)

- [UEG Week](http://www.protagonist-inc.com/events-presentations/ueg-week)

- [41st Annual J.P. Morgan Health Care Conference](http://www.protagonist-inc.com/events-presentations/41st-annual-j-p-morgan-health-care-conference)

- [Cyclic tetrapeptides via the ring contraction strategy: chemical techniques useful for their identification](http://www.protagonist-inc.com/publications/cyclic-tetrapeptides-via-the-ring-contraction-strategy-chemical-techniques-useful-for-their-identification)

- [Library of biphenyl privileged substructures using a safety-catch linker approach](http://www.protagonist-inc.com/publications/library-of-biphenyl-privileged-substructures-using-a-safety-catch-linker-approach)

- [Defining scaffold geometries for interacting with proteins: geometrical classification of secondary structure linking regions](http://www.protagonist-inc.com/publications/defining-scaffold-geometries-for-interacting-with-proteins-geometrical-classification-of-secondary-structure-linking-regions)

- [Conformational searching using a population-based incremental learning algorithm](http://www.protagonist-inc.com/publications/conformational-searching-using-a-population-based-incremental-learning-algorithm)

- [Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo](http://www.protagonist-inc.com/publications/discovery-and-characterization-of-a-potent-interleukin-6-binding-peptide-with-neutralizing-activity-in-vivo)

- [Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23](http://www.protagonist-inc.com/publications/clustering-of-disulfide-rich-peptides-provides-scaffolds-for-hit-discovery-by-phage-display-application-to-interleukin-23)

- [Orally Delivered Peptides for Treatment of Inflammatory Bowel Disease](http://www.protagonist-inc.com/publications/orally-delivered-peptides-for-treatment-of-inflammatory-bowel-disease)

- [Oral peptides with dual mu/delta opioid receptor agonist activities are superior to eluxadoline in preclinical models of IBS-D](http://www.protagonist-inc.com/publications/oral-peptides-with-dual-mu-delta-opioid-receptor-agonist-activities-are-superior-to-eluxadoline-in-preclinical-models-of-ibs-d)

- [Discovery and Characterization of Novel Oral Peptide Antagonists of Human IL-23 Receptor that are Efficacious in a Rat Model of IBD](http://www.protagonist-inc.com/publications/discovery-and-characterization-of-novel-oral-peptide-antagonists-of-human-il-23-receptor-that-are-efficacious-in-a-rat-model-of-ibd)

- [Discovery of Novel Oral Peptide Antagonists of IL-23 Receptor that are Efficacious in Rat Model of IBD](http://www.protagonist-inc.com/publications/discovery-of-novel-oral-peptide-antagonists-of-il-23-receptor-that-are-efficacious-in-rat-model-of-ibd)

- [The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in Preclinical Model of IBD](http://www.protagonist-inc.com/publications/the-biomarker-profile-of-ptg-200-an-oral-peptide-antagonist-of-il-23-receptor-tracks-with-efficacy-in-preclinical-model-of-ibd)

- [(UEGW 2019) Safety, Tolerability, And Pharmacokinetics Of PTG-200, An Oral Gi-Restricted Peptide Antagonist Of IL-23 Receptor, In Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/uegw-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers)

- [(ACG 2019) Safety, Tolerability, and Pharmacokinetics of PTG-200, An Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, In Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/acg-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers)

- [Integrin α4β7: Discovery of Gut-Restrictive Oral Peptide Antagonists that are Active in Murine Models of Inflammatory Bowel Disease](http://www.protagonist-inc.com/publications/integrin-47-discovery-of-gut-restrictive-oral-peptide-antagonists-that-are-active-in-murine-models-of-inflammatory-bowel-disease)

- [Preclinical Characterization of PTG-100, an Oral α4β7 Integrin Peptide Antagonist for Treatment of Ulcerative Colitis](http://www.protagonist-inc.com/publications/preclinical-characterization-of-ptg-100-an-oral-47-integrin-peptide-antagonist-for-treatment-of-ulcerative-colitis)

- [PTG-100, an Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models](http://www.protagonist-inc.com/publications/ptg-100-an-oral-peptide-antagonist-of-integrin-47-that-alters-trafficking-of-gut-homing-t-cells-in-preclinical-animal-models)

- [Establishing the Human Equivalent Dose for PTG-100, an Oral Peptide Antagonist of Integrin α4β7](http://www.protagonist-inc.com/publications/establishing-the-human-equivalent-dose-for-ptg-100-an-oral-peptide-antagonist-of-integrin-47)

- [Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (α4β7 Integrin Antagonist) in Normal Healthy Volunteers](http://www.protagonist-inc.com/publications/safety-pharmacokinetics-and-pharmacodynamics-of-the-novel-oral-peptide-therapeutic-ptg-100-47-integrin-antagonist-in-normal-healthy-volunteers)

- [Pharmacokinetics and Pharmacodynamics Following Oral Administration Of PTG-100, a Peptide Antagonist of Integrin α4β7](http://www.protagonist-inc.com/publications/pharmacokinetics-and-pharmacodynamics-following-oral-administration-of-ptg-100-a-peptide-antagonist-of-integrin-47)

- [Model Based Predictions of the PTG-100 Pharmacodynamic Responses in Ulcerative Colitis Patients](http://www.protagonist-inc.com/publications/model-based-predictions-of-the-ptg-100-pharmacodynamic-responses-in-ulcerative-colitis-patients)

- [PTG-100, an Oral Gut-Restricted Peptide α4β7 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis](http://www.protagonist-inc.com/publications/ptg-100-an-oral-gut-restricted-peptide-47-antagonist-induces-clinical-and-histologic-remission-in-patients-with-moderate-to-severely-active-ulcerative-colitis)

- [The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective than PTG-100 in Multiple Preclinical Studies](http://www.protagonist-inc.com/publications/the-oral-47-integrin-specific-antagonist-pn-10943-is-more-effective-than-ptg-100-in-multiple-preclinical-studies)

- [PN-943, an Oral α4β7 Integrin Antagonist, Inhibits MAdCAM1-Mediated Proliferation and Cytokine Release from CD4+ T-Cells Independent of Trafficking](http://www.protagonist-inc.com/publications/pn-943-an-oral-47-integrin-antagonist-inhibits-madcam1-mediated-proliferation-and-cytokine-release-from-cd4--t-cells-independent-of-trafficking)

- [Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers](http://www.protagonist-inc.com/publications/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers)

- [A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the safety and efficacy of the oral, gut-restricted ɑ4β7 integrin peptide antagonist PN-943](http://www.protagonist-inc.com/publications/a-phase-2-randomized-double-blind-placebocontrolled-multi-center-study-to-evaluate-the-safety-and-efficacy-of-the-oral-gut-restricted-47-integrin-peptide-antagonist-pn-943)

- [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload)

- [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Iron Overload Diseases](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload-diseases)

- [Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Diseases](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases)

- [Hepcidin Mimetic PTG-300 Induces Dose-Related and Sustained Reductions in Serum Iron and Transferrin Saturation in Healthy Subjects](http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects)

- [Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-and-hereditary-hemochromatosis)

- [Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models](http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models-nov-2020)

- [PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients](http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients-dec-2020)

- [Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis](http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-of-iron-overload-and-erythrocytosis)

- [PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients](http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients)

- [Regulation of Iron Homeostasis by PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia & Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-hereditary-hemochromatosis)

- [Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models](http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models)

- [Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Models for Iron Overload and Erythrocytosis](http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-for-iron-overload-and-erythrocytosis)

- [The Hepcidin Mimetic Rusfertide as a Treatment for Hereditary Hemochromatosis](http://www.protagonist-inc.com/publications/the-hepcidin-mimetic-rusfertide-as-a-treatment-for-hereditary-hemochromatosis)

- [PTG-300 (Rusfertide) Treatment Interruption Reverses Hematological Gains And Restores Therapeutic Benefit On Reinitiation In Subjects With Polycythemia Vera](http://www.protagonist-inc.com/publications/ptg-300-rusfertide-treatment-interruption-reverses-hematological-gains-and-restores-therapeutic-benefit-on-reinitiation-in-subjects-with-polycythemia-vera)

- [Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment](http://www.protagonist-inc.com/publications/rusfertide-for-polycythemia-vera-similar-dosing-in-patients-receiving-therapeutic-phlebotomy-alone-or-in-combination-with-cytoreductive-treatment)

- [Subgroup Analysis of Adverse Events Following Rusfertide Dosing in REVIVE: A Phase 2 Study in Patients with Polycythemia Vera](http://www.protagonist-inc.com/publications/subgroup-analysis-of-adverse-events-following-rusfertide-dosing-in-revive-a-phase-2-study-in-patients-with-polycythemia-vera)

- [BMO Capital Markets, Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-prescriptions-for-success-healthcare-conference)

- [2016 Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America’s Clinical & Research Conference](http://www.protagonist-inc.com/events-presentations/2016-advances-in-inflammatory-bowel-diseases-crohns-colitis-foundation-of-americas-clinical-research-conference)

- [BioEurope 2016](http://www.protagonist-inc.com/events-presentations/bioeurope-2016)

- [Protagonist Therapeutics Inc at 252nd American Chemical Society National Meeting & Exposition](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-252nd-american-chemical-society-national-meeting-exposition)

- [BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference)

- [Protagonist Therapeutics Inc at Stifel 2017 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-stifel-2017-healthcare-conference)

- [2017 Cantor Fitzgerald Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/2017-cantor-fitzgerald-global-healthcare-conference)

- [Protagonist Business Update](http://www.protagonist-inc.com/events-presentations/protagonist-business-update)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-25-2017)

- [Digestive Diseases Week](http://www.protagonist-inc.com/events-presentations/digestive-diseases-week)

- [Oxford Global’s 4th Annual Peptide Congress](http://www.protagonist-inc.com/events-presentations/oxford-globals-4th-annual-peptide-congress)

- [Drug Discovery Chemistry](http://www.protagonist-inc.com/events-presentations/drug-discovery-chemistry)

- [Oppenheimer & Co. Healthcare Conference](http://www.protagonist-inc.com/events-presentations/oppenheimer-co-healthcare-conference)

- [Barclays Global Healthcare Conference 2017](http://www.protagonist-inc.com/events-presentations/barclays-global-healthcare-conference-2017)

- [Leerink Partners 6th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-6th-annual-global-healthcare-conference)

- [12th Congress of ECCO (European Crohn's and Colitis Organization)](http://www.protagonist-inc.com/events-presentations/12th-congress-of-ecco-european-crohn-s-and-colitis-organization)

- [BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference)

- [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-2018)

- [United European Gastroenterology Week Meeting](http://www.protagonist-inc.com/events-presentations/united-european-gastroenterology-week-meeting)

- [Cantor Fitzgerald Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/cantor-fitzgerald-global-healthcare-conference)

- [PROPEL Study and PTG-100 Program Update Conference Call](http://www.protagonist-inc.com/events-presentations/propel-study-and-ptg-100-program-update-conference-call)

- [2018 JMP Securities Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/2018-jmp-securities-life-sciences-conference)

- [Hepcidin mimetic PTG-300 for treatment of ineffective erythropoiesis and chronic anemia in hemoglobinopathy diseases](http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases)

- [Hepcidin Mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects](http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects)

- [23rd Congress of the European Hematology Association (EHA)](http://www.protagonist-inc.com/events-presentations/23rd-congress-of-the-european-hematology-association-eha)

- [Digestive Diseases Week® (DDW) Conference](http://www.protagonist-inc.com/events-presentations/digestive-diseases-week-ddw-conference)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-29-2018)

- [Protagonist Therapeutics Inc Conference Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-conference-call)

- [Protagonist Therapeutics Inc at 28th Annual Oppenheimer Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-28th-annual-oppenheimer-healthcare-conference)

- [Protagonist Therapeutics Inc at Barclay's Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-barclay-s-global-healthcare-conference)

- [Protagonist Therapeutics, Inc. 2017 Year-End Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-2017-year-end-update-call)

- [BTIG’s 2018 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/btigs-2018-healthcare-conference)

- [Leerink Partners 7th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-7th-annual-global-healthcare-conference)

- [Piper Healthcare Conference](http://www.protagonist-inc.com/events-presentations/piper-healthcare-conference)

- [PTG-300 beta-thalassemia update](http://www.protagonist-inc.com/events-presentations/ptg-300-beta-thalassemia-update)

- [Stifel 2019 Healthcare Conference](http://www.protagonist-inc.com/events-presentations/stifel-2019-healthcare-conference)

- [Cantor Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/cantor-global-healthcare-conference)

- [Protagonist at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-2019-annual-healthcare-conference)

- [BMO 2019 Prescription for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-2019-prescription-for-success-healthcare-conference)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-jun-7-2019)

- [Digestive Disease Week (DDW)](http://www.protagonist-inc.com/events-presentations/digestive-disease-week-ddw)

- [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-may-8-2019)

- [Protagonist at the H.C. Wainwright & Co. Global Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-global-life-sciences-conference)

- [Q4 2018 Protagonist Therapeutics Inc Earnings Conference Call](http://www.protagonist-inc.com/events-presentations/q4-2018-protagonist-therapeutics-inc-earnings-conference-call)

- [Leerink Partners 8th Annual Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/leerink-partners-8th-annual-global-healthcare-conference)

- [Research and Development (R&D) and Corporate Update](http://www.protagonist-inc.com/events-presentations/research-and-development-r-d-and-corporate-update)

- [62nd ASH Annual Meeting and Exposition](http://www.protagonist-inc.com/events-presentations/62nd-ash-annual-meeting-and-exposition)

- [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference-2020)

- [Protagonist at the H.C. Wainwright 22nd Annual Global Investment Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-22nd-annual-global-investment-conference)

- [Protagonist at the Jefferies Next Generation IBD Therapeutics Virtual Summit](http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-virtual-summit)

- [Protagonist Therapeutics PTG-300 Opportunity Update Webinar](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-ptg-300-opportunity-update-webinar)

- [BMO Prescriptions for Success Healthcare Conference](http://www.protagonist-inc.com/events-presentations/bmo-prescriptions-for-success-healthcare-conference)

- [Protagonist at the Jefferies Virtual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference-jun-3-2020)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-28-2020)

- [Protagonist Corporate and R&D Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-and-r-d-update-call)

- [Protagonist Therapeutics 2019 Year-End Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-2019-year-end-update-call)

- [SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/svb-leerink-global-healthcare-conference)

- [ASH 2021 Presentation](http://www.protagonist-inc.com/events-presentations/ash-2021-presentation)

- [JMP Securities Hematology and Oncology Summit - 1:40 PM ET](http://www.protagonist-inc.com/events-presenations/jmp-securities-hematology-and-oncology-summit-1-40-pm-et)

- [Piper Sandler 33rd Annual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/piper-sandler-33rd-annual-healthcare-conference)

- [Protagonist at the Jefferies London Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference)

- [The Liver Meeting®: AASLD 2021 Oral Presentation](http://www.protagonist-inc.com/events-presentations/the-liver-meeting-aasld-2021-oral-presentation)

- [Protagonist at the Jefferies Next Generation IBD Therapeutics Summit](http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-summit)

- [Protagonist Regulatory Update Conference Call](http://www.protagonist-inc.com/events-presentations/protagonist-regulatory-update-conference-call)

- [Investor Call on Updated Janssen Agreement](http://www.protagonist-inc.com/events-presentations/investor-call-on-updated-janssen-agreement)

- [European Hematology Association ("EHA") 2021 Annual Congress](http://www.protagonist-inc.com/events-presentations/european-hematology-association-eha-2021-annual-congress)

- [EHA2021 Corporate Event: Conference Call and Webcast](http://www.protagonist-inc.com/events-presentations/eha2021-corporate-event-conference-call-and-webcast)

- [Protagonist at the Jefferies Virtual Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-2021)

- [Protagonist Corporate Update Call](http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call)

- [Protagonist Therapeutics Fourth Quarter and Year-end Financial Results](http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-fourth-quarter-and-year-end-financial-results)

- [Protagonist at the H.C. Wainwright Global Life Sciences Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-global-life-sciences-conference)

- [10th Annual SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/10th-annual-svb-leerink-global-healthcare-conference)

- [39th Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/39th-annual-j-p-morgan-healthcare-conference)

- [Protagonist at the H.C. Wainwright BioConnect 2022 Conference](http://www.protagonist-inc.com/events-presentations/h-c-wainwright-bioconnect-2022-conference)

- [40th Annual J.P. Morgan Healthcare Conference](http://www.protagonist-inc.com/events-presentations/40th-annual-j-p-morgan-healthcare-conference)

- [11th Annual SVB Leerink Global Healthcare Conference](http://www.protagonist-inc.com/events-presentations/11th-annual-svb-leerink-global-healthcare-conference)

- [PN-943 Phase 2 Data Readout – Conference Call](http://www.protagonist-inc.com/events-presentations/pn-943-phase-2-data-readout-conference-call)

- [IDEAL PN-943 DDW 2022 Presentation](http://www.protagonist-inc.com/events-presentations/ideal-pn-943-ddw-2022-presentation)

- [Annual Meeting of Stockholders](http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders)

- [ASCO 2022 Presentation](http://www.protagonist-inc.com/events-presentations/asco-2022-presentation)

- [Protagonist at the Jefferies Healthcare Conference](http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference)

- [EHA 2022 Poster Presentation](http://www.protagonist-inc.com/events-presentations/eha-2022-poster-presentation)

- [California Life Sciences Cancer Moonshot](http://www.protagonist-inc.com/events-presentations/california-life-sciences-cancer-moonshot)

- [SOHO Rusfertide Presentation](http://www.protagonist-inc.com/events-presentations/soho-rusfertide-presentation)

- [ASH 2022 Poster Presentation: VERIFY: A Phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera](http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation-dec-10-2022)

- [ASH Annual Meeting & Exposition](http://www.protagonist-inc.com/events-presentations/ash-annual-meeting-exposition)

- [ASH 2022 Poster Presentation: Subgroup analysis of Adverse Events following rusfertide dosing in REVIVE: A Phase 2 study in patients with polycythemia vera](http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation)





Version History

Version 111/16/2026, 4:02:29 AMvalid
58743 bytes

Categories

blognewstechnologybusinesshealth

Visit Website

Explore the original website and see their AI training policy in action.

Visit protagonist-inc.com

Content Types

postspagesapi

Recent Access

No recent access

API Access

Canonical URL:
https://llmscentral.com/protagonist-inc.com/llms.txt
API Endpoint:
/api/llms?domain=protagonist-inc.com
protagonist-inc.com - llms.txt File | AI Training Guidelines | LLMS Central